{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:10:50Z","timestamp":1780341050468,"version":"3.54.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T00:00:00Z","timestamp":1624752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13555-021-00571-3","type":"journal-article","created":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T07:02:25Z","timestamp":1624777345000},"page":"1217-1237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature"],"prefix":"10.1007","volume":"11","author":[{"given":"Aleksandra","family":"Opali\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Kwiatkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Burdacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miros\u0142aw","family":"Markiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Samotij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Dudzi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Niemiec-Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Osta\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-1754","authenticated-orcid":false,"given":"Adam","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,27]]},"reference":[{"key":"571_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/bmj.333.7560.181","volume":"333","author":"T Brooklyn","year":"2006","unstructured":"Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. Br Med J. 2006;333:181\u20134.","journal-title":"Br Med J"},{"key":"571_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaad.2015.06.021","volume":"73","author":"SF Braswell","year":"2015","unstructured":"Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73:691\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1111\/bjd.13493","volume":"172","author":"EM DeFilippis","year":"2015","unstructured":"DeFilippis EM, Feldman SR, Huang WW. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol. 2015;172:1487\u201397.","journal-title":"Br J Dermatol"},{"key":"571_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/j.jaad.2019.09.032","volume":"82","author":"CM Montagnon","year":"2020","unstructured":"Montagnon CM, Fracica EA, Patel AA, et al. Pyoderma gangrenosum in hematologic malignancies: a systematic review. J Am Acad Dermatol. 2020;82:1346\u201359.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17512433.2020.1709825","volume":"13","author":"M Goldust","year":"2020","unstructured":"Goldust M, Hagstrom EL, Rathod D, et al. Diagnosis and novel clinical treatment strategies for pyoderma gangrenosum. Expert Rev Clin Pharmacol. 2020;13:157\u201361.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"571_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2004.10.006","volume":"53","author":"J Reichrath","year":"2005","unstructured":"Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273\u201383.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/0141076814534407","volume":"107","author":"A Teagle","year":"2014","unstructured":"Teagle A, Hargest R. Management of pyoderma gangrenosum. J R Soc Med. 2014;107:228\u201336.","journal-title":"J R Soc Med"},{"key":"571_CR8","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118:4041.","journal-title":"Blood"},{"key":"571_CR9","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00277-015-2350-y","volume":"94","author":"BI Dalal","year":"2015","unstructured":"Dalal BI, Vakil AP, Khare NS, et al. Abnormalities of the lymphocyte subsets and their immunophenotype, and their prognostic significance in adult patients with hemophagocytic lymphohistiocytosis. Ann Hematol. 2015;94:1111\u20137.","journal-title":"Ann Hematol"},{"key":"571_CR10","doi-asserted-by":"publisher","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","volume":"16","author":"A Filipovich","year":"2010","unstructured":"Filipovich A, McClain K, Grom A. Histiocytic disorders: recent insights into pathophysiology and practical guidelines. Biol Blood Marrow Transplant. 2010;16:S82.","journal-title":"Biol Blood Marrow Transplant"},{"key":"571_CR11","unstructured":"Saxena R, Pati HP, Mahapatra M. Atlas of hematology. New Delhi: Jaypee Brothers Medical Publishers; 2012. 110 p. ISBN 978-93-5025-508-7."},{"key":"571_CR12","unstructured":"Naeim F, Rao NP, Song SX, Grody WW. Atlas of hematopathology: morphology, immunophenotype, cytogenetics, and molecular approaches, 1st ed. London: Academic; 2013. ISBN 13: 9780123851833, ISBN 10: 0123851831."},{"key":"571_CR13","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1182\/asheducation-2009.1.127","volume":"2009","author":"AH Filipovich","year":"2009","unstructured":"Filipovich AH. Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009;2009:127\u201331.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"571_CR14","first-page":"997","volume":"100","author":"K Lehmberg","year":"2015","unstructured":"Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies. Haematologica. 2015;100:997\u20131004.","journal-title":"Haematologica"},{"key":"571_CR15","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.13102","volume":"168","author":"M Arca","year":"2015","unstructured":"Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168:63\u20138.","journal-title":"Br J Haematol"},{"key":"571_CR16","first-page":"726","volume":"10","author":"RL Kleynberg","year":"2012","unstructured":"Kleynberg RL, Schiller GJ. Secondary hemophagocytic lymphohistiocytosis in adults: an update on diagnosis and therapy. Clin Adv Hematol Oncol. 2012;10:726\u201332.","journal-title":"Clin Adv Hematol Oncol"},{"key":"571_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124\u201331.","journal-title":"Pediatr Blood Cancer"},{"key":"571_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2174\/157488412803305821","volume":"7","author":"N Pazyar","year":"2012","unstructured":"Pazyar N, Feily A, Yaghoobi R. An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr Clin Pharmacol. 2012;7:271\u20135.","journal-title":"Curr Clin Pharmacol"},{"key":"571_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10354-014-0285-x","volume":"164","author":"U Wollina","year":"2014","unstructured":"Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr. 2014;164:263\u201373.","journal-title":"Wien Med Wochenschr"},{"key":"571_CR20","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G, et al. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199\u2013201.","journal-title":"Br J Dermatol"},{"key":"571_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","volume":"66","author":"M Braun-Falco","year":"2012","unstructured":"Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2014a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/RHU.0000000000000511","volume":"23","author":"C Beynon","year":"2017","unstructured":"Beynon C, Chin MF, Hunasehally P, et al. Successful treatment of autoimmune disease-associated pyoderma gangrenosum with the IL-1 receptor antagonist anakinra: a case series of 3 patients. J Clin Rheumatol. 2017;23:181\u20133.","journal-title":"J Clin Rheumatol"},{"key":"571_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.7326\/L15-5107","volume":"163","author":"M Acquitter","year":"2015","unstructured":"Acquitter M, Plantin P, Kupfer I, et al. Anakinra improves pyoderma gangrenosum in psoriatic arthritis: a case report. Ann Intern Med. 2015;163:70\u20131.","journal-title":"Ann Intern Med"},{"key":"571_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","volume":"34","author":"P Wohlfarth","year":"2019","unstructured":"Wohlfarth P, Agis H, Gualdoni GA, et al. Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med. 2019;34:723\u201331.","journal-title":"J Intensive Care Med"},{"key":"571_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, et al. Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72:326\u201334.","journal-title":"Arthritis Rheumatol"},{"key":"571_CR26","doi-asserted-by":"publisher","first-page":"h2958","DOI":"10.1136\/bmj.h2958","volume":"350","author":"AD Ormerod","year":"2015","unstructured":"Ormerod AD, Thomas KS, Craig FE, et al. Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial. BMJ. 2015;350:h2958.","journal-title":"BMJ"},{"key":"571_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MGS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo-controlled trial. Gut. 2006;55:505\u20139.","journal-title":"Gut"},{"key":"571_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1365-2230.2010.03941.x","volume":"36","author":"RM Bhat","year":"2011","unstructured":"Bhat RM, Nandakishore B, Sequeira FF, et al. Pyoderma gangrenosum: An Indian perspective. Clin Exp Dermatol. 2011;36:242\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"571_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3109\/09546631003686069","volume":"22","author":"AV Marzano","year":"2011","unstructured":"Marzano AV, Trevisan V, Lazzari R, et al. Pyoderna gangrenosum: a study of 21 patients and proposal of a \u2018clinicotherapeutic\u2019 classification. J Dermatolog Treat. 2011;22:254\u201360.","journal-title":"J Dermatolog Treat"},{"key":"571_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/095466301750163518","volume":"12","author":"CC Lyon","year":"2001","unstructured":"Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. J Dermatolog Treat. 2001;12:13\u20137.","journal-title":"J Dermatolog Treat"},{"key":"571_CR31","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","volume":"58","author":"F Arg\u00fcelles-Arias","year":"2013","unstructured":"Arg\u00fcelles-Arias F, Castro-Laria L, Lobat\u00f3n T, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58:2949\u201354.","journal-title":"Dig Dis Sci"},{"key":"571_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/1534734616639172","volume":"15","author":"E Adi\u015fen","year":"2016","unstructured":"Adi\u015fen E, Erduran F, G\u00fcrer MA. Pyoderma gangrenosum: a report of 27 patients. Int J Low Extrem Wounds. 2016;15:148\u201354.","journal-title":"Int J Low Extrem Wounds"},{"key":"571_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/DCR.0b013e31819accc6","volume":"52","author":"Y Funayama","year":"2009","unstructured":"Funayama Y, Kumagai E, Takahashi KI, Fukushima K, Sasaki I. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease. Dis Colon Rectum. 2009;52:311\u20134.","journal-title":"Dis Colon Rectum"},{"key":"571_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaad.2013.05.028","volume":"69","author":"J Li","year":"2013","unstructured":"Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013;69:565\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR35","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1365-4632.2011.05451.x","volume":"52","author":"N Pereira","year":"2013","unstructured":"Pereira N, Brites MM, Gon\u00e7alo M, Tellechea \u00d3, Figueiredo A. Pyoderma gangrenosum\u2014a review of 24 cases observed over 10years. Int J Dermatol. 2013;52:938\u201345.","journal-title":"Int J Dermatol"},{"key":"571_CR36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjd.15850","volume":"178","author":"H Song","year":"2018","unstructured":"Song H, Lahood N, Mostaghimi A. Intravenous immunoglobulin as adjunct therapy for refractory pyoderma gangrenosum: systematic review of cases and case series. Br J Dermatol. 2018;178:363\u20138.","journal-title":"Br J Dermatol"},{"key":"571_CR37","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/09546630903268239","volume":"21","author":"AV Marzano","year":"2010","unstructured":"Marzano AV, Trevisan V, Lazzari R, et al. Topical tacrolimus for the treatment of localized, idiopathic, newly diagnosed pyoderma gangrenosum. J Dermatolog Treat. 2010;21:140\u20133.","journal-title":"J Dermatolog Treat"},{"key":"571_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1365-2133.2007.08433.x","volume":"158","author":"A Kreuter","year":"2008","unstructured":"Kreuter A, Reich-Schupke S, Stucker M, et al. Intravenous immunoglobulin for pyoderma gangrenosum. Br J Dermatol. 2008;158:856\u20137.","journal-title":"Br J Dermatol"},{"key":"571_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/j.1365-2133.2007.08217.x","volume":"157","author":"DL Cummins","year":"2007","unstructured":"Cummins DL, Anhalt GJ, Monahan T, Meyerle JH. Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol. 2007;157:1235\u20139.","journal-title":"Br J Dermatol"},{"key":"571_CR40","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/0190-9622(95)90218-X","volume":"32","author":"AK Gupta","year":"1995","unstructured":"Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol. 1995;32:140\u20132.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR41","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/bjd.14619","volume":"175","author":"K Herberger","year":"2016","unstructured":"Herberger K, Dissemond J, Hohaus K, et al. Treatment of pyoderma gangrenosum: retrospective multicentre analysis of 121 patients. Br J Dermatol. 2016;175:1070\u20132.","journal-title":"Br J Dermatol"},{"key":"571_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-017-0251-7","volume":"18","author":"A Alavi","year":"2017","unstructured":"Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18:355\u201372.","journal-title":"Am J Clin Dermatol"},{"key":"571_CR43","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.12688\/f1000research.19909.1","volume":"8","author":"J Fletcher","year":"2019","unstructured":"Fletcher J, Raed A, Afsaneh A. Recent advances in managing and understanding pyoderma gangrenosum. F1000Res. 2019;8:2092.","journal-title":"F1000Res"},{"key":"571_CR44","first-page":"34","volume":"5","author":"SR Quist","year":"2017","unstructured":"Quist SR, Kraas L. Treatment options for pyoderma gangrenosum. J Dtsch Dermatol Ges. 2017;5:34\u201340.","journal-title":"J Dtsch Dermatol Ges"},{"key":"571_CR45","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/09546634.2018.1506083","volume":"30","author":"F McKenzie","year":"2019","unstructured":"McKenzie F, Cash D, Gupta A. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat. 2019;30:264\u201376.","journal-title":"J Dermatolog Treat"},{"key":"571_CR46","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/1346-8138.15533","volume":"47","author":"K Yamasaki","year":"2000","unstructured":"Yamasaki K, Yamanaka K, Zhao Y, et al. Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: twenty-six-week phase 3 open-label study. J Dermatol. 2000;47:1383\u201390.","journal-title":"J Dermatol"},{"key":"571_CR47","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-4632.2007.03286.x","volume":"46","author":"CA Charles","year":"2007","unstructured":"Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007;46:1095\u20139.","journal-title":"Int J Dermatol"},{"key":"571_CR48","first-page":"441","volume":"3","author":"JW McGowan","year":"2004","unstructured":"McGowan JW, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol. 2004;3:441\u20134.","journal-title":"J Drugs Dermatol"},{"key":"571_CR49","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2230.2005.01972.x","volume":"31","author":"N Pastor","year":"2006","unstructured":"Pastor N, Betlloch I, Pascual JC, Blanes M, Banuls J, Silvestre JF. Pyoderma gangrenosum treated with anti-TNF alpha therapy (etanercept). Clin Exp Dermatol. 2006;31:152\u20133.","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl 2","key":"571_CR50","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/j.jaad.2005.10.058","volume":"54","author":"DB Roy","year":"2006","unstructured":"Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(Suppl 2):S128\u201334.","journal-title":"J Am Acad Dermatol"},{"key":"571_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/09546630500424722","volume":"16","author":"G Goldenberg","year":"2005","unstructured":"Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatolog Treat. 2005;16:347\u20139.","journal-title":"J Dermatolog Treat"},{"key":"571_CR52","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.bjps.2006.11.011","volume":"61","author":"FJ Rogge","year":"2008","unstructured":"Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNF alpha drug\u2014etanercept. J Plast Reconstr Aesthet Surg. 2008;61:431\u20133.","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"571_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/01.rhu.0000111315.94725.9c","volume":"10","author":"E Disla","year":"2004","unstructured":"Disla E, Quayum B, Cuppari GG, Pancorbo R. Successful use of etanercept in a patient with pyoderma gangrenosum complicating rheumatoid arthritis. J Clin Rheumatol. 2004;10:50\u20132.","journal-title":"J Clin Rheumatol"},{"key":"571_CR54","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1111\/ajd.12545","volume":"58","author":"M Benzaquen","year":"2017","unstructured":"Benzaquen M, Monnier J, Beaussault Y, et al. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: effectiveness of ustekinumab. Australas J Dermatol. 2017;58:e270\u20131.","journal-title":"Australas J Dermatol"},{"key":"571_CR55","doi-asserted-by":"publisher","first-page":"e12928","DOI":"10.1111\/dth.12928","volume":"32","author":"F Diotallevi","year":"2019","unstructured":"Diotallevi F, Campanati A, Radi G, et al. Pyoderma gangrenosum successfully treated with golimumab: case report and review of the literature. Dermatol Ther. 2019;32:e12928.","journal-title":"Dermatol Ther"},{"key":"571_CR56","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1111\/bjd.14037","volume":"173","author":"AG Kolios","year":"2015","unstructured":"Kolios AG, Maul JT, Meier B, et al. Canakinumab in adults with steroid-refractory pyoderma gangrenosum. Br J Dermatol. 2015;173:1216\u201323.","journal-title":"Br J Dermatol"},{"key":"571_CR57","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1309\/AJCPP40MEXWYRLPN","volume":"137","author":"CM McCall","year":"2012","unstructured":"McCall CM, Mudali S, Arceci RJ, et al. Flow cytometric findings in hemophagocytic lymphohistiocytosis. Am J Clin Pathol. 2012;137:786\u201394.","journal-title":"Am J Clin Pathol"},{"key":"571_CR58","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3343\/alm.2019.39.5.430","volume":"39","author":"MS Park","year":"2019","unstructured":"Park MS, Yoo IY, Kim HJ, et al. Flow cytometric analysis of T cells in hemophagocytic lymphohistiocytosis. Ann Lab Med. 2019;39:430\u20137.","journal-title":"Ann Lab Med"},{"key":"571_CR59","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.4049\/jimmunol.172.3.1637","volume":"172","author":"SC De Rosa","year":"2004","unstructured":"De Rosa SC, Andrus JP, Perfetto SP, et al. Ontogeny of \u03b3\u03b4 T cells in humans. J Immunol. 2004;172:1637\u201345.","journal-title":"J Immunol"},{"issue":"suppl.24","key":"571_CR60","first-page":"45","volume":"35","author":"A Pituch-Noworolska","year":"2008","unstructured":"Pituch-Noworolska A. Immunophenotype of mature hematopoietic cells\u2014primary and secondary immunodeficiences. Post Biol Kom. 2008;35(suppl.24):45\u201354.","journal-title":"Post Biol Kom"},{"key":"571_CR61","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.5858\/132.11.1774","volume":"132","author":"AC Roden","year":"2008","unstructured":"Roden AC, Morice WG, Hanson CA, et al. Immunophenotypic attributes of benign peripheral blood \u03b3\u03b4 T Cells and conditions associated with their increase. Arch Pathol Lab Med. 2008;132:1774\u201380.","journal-title":"Arch Pathol Lab Med"},{"key":"571_CR62","first-page":"81","volume":"2","author":"M Prochorec-Sobieszek","year":"2009","unstructured":"Prochorec-Sobieszek M. Characteristics of T-cell large granular lymphocyte proliferaitons. J Transf Med. 2009;2:81\u2013135.","journal-title":"J Transf Med"},{"key":"571_CR63","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1182\/blood.V120.21.3267.3267","volume":"120","author":"BI Dalal","year":"2012","unstructured":"Dalal BI, Khare NS, Wang SY, et al. Diverse immunophenotypic abnormalities in adult patients with hemophagocytic lymphohistiocytosis. Blood. 2012;120:3267.","journal-title":"Blood"},{"key":"571_CR64","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21608\/ejpa.2019.41533","volume":"17","author":"EM Hossny","year":"2019","unstructured":"Hossny EM, El-Owaidy RH, Afifi HM, Ahmed HR. Double negative alpha beta T cells in pediatric hemophagocytic syndromes. Egypt J Pediatr Allergy Immunol. 2019;17:13\u20139.","journal-title":"Egypt J Pediatr Allergy Immunol"},{"key":"571_CR65","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134:1783\u20136.","journal-title":"Blood"},{"key":"571_CR66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1358\/dot.2020.56.7.3145359","volume":"56","author":"AZ Cheloff","year":"2020","unstructured":"Cheloff AZ, Al-Samkari H. Emapalumab for the treatment of hemophagocytic lymphohistiocytosis. Drugs Today (Barc). 2020;56:439\u201346.","journal-title":"Drugs Today (Barc)"},{"key":"571_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcaa011","author":"H Yildiz","year":"2020","unstructured":"Yildiz H, Van Den Neste E, Defour JP, et al. Adult haemophagocytic lymphohistiocytosis: a review. QJM. 2020. https:\/\/doi.org\/10.1093\/qjmed\/hcaa011.","journal-title":"QJM"},{"key":"571_CR68","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6:e630\u20137.","journal-title":"Lancet Haematol"},{"key":"571_CR69","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1182\/bloodadvances.2019000898","volume":"3","author":"SR Goldsmith","year":"2019","unstructured":"Goldsmith SR, Rehman SSU, Shirai CL, et al. Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1\/2 inhibitor ruxolitinib. Blood Adv. 2019;3:4131\u20135.","journal-title":"Blood Adv"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00571-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00571-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T04:09:11Z","timestamp":1627618151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00571-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,27]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00571-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,27]]},"assertion":[{"value":"5 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}